Which medications in the drug class Antineoplastics, BRAF Kinase Inhibitor are used in the treatment of Colon Cancer?

Updated: Apr 15, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

Antineoplastics, BRAF Kinase Inhibitor

This pathway regulates several key cellular activities, including proliferation, differentiation, survival, and angiogenesis; inappropriate activation of proteins in this pathway has been shown to occur in many cancers.

Encorafenib (Braftovi)

Encorafenib inhibits in vitro growth of tumor cell lines expressing BRAF V600 E, D, and K mutations. It is indicated in combination with cetuximab for metastatic colorectal cancer (CRC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!